Highest-materiality recent filing
All nine director nominees elected, including Jessica Blume, Kenneth Burdick, Christopher Coughlin; shareholder votes ratified KPMG as auditor.
Centene Q1 2026 GAAP EPS $3.11, Adjusted EPS $3.37; Raises 2026 Guidance
GAAP diluted EPS $3.11, adjusted diluted EPS $3.37 (~$0.50 above expectations).
Centene appoints Theodore Pienkos as Corporate Controller and CAO effective March 18, 2026
Pienkos, 44, CPA, previously Deputy Corporate Controller since Aug 2024; joined Centene in 2011.
Centene reaffirms FY2026 guidance and redeems $1B of 4.25% notes due 2027
Reaffirmed 2026 GAAP diluted EPS guidance > $1.98 and adjusted diluted EPS > $3.00 at Barclays conference.
Centene reaffirms 2026 EPS guidance of >$1.98 GAAP, >$3.00 adjusted
Reaffirms 2026 GAAP diluted EPS guidance of greater than $1.98.
Centene reports FY 2025 GAAP loss of $13.53 per share; guides FY 2026 adj. EPS >$3.00
Full-year GAAP diluted loss per share $(13.53) includes $6.7B goodwill impairment; adjusted diluted EPS $2.08.
Centene reaffirms FY2025 guidance: GAAP loss <= $(12.85), adj. EPS >= $2.00
Full-year GAAP diluted loss per share expected not to exceed $(12.85).
Centene Q3 GAAP loss $(13.50) from $6.7B impairment; adjusted EPS $0.50; raises FY guide to $2.00
GAAP diluted loss per share $(13.50) driven by $6.7B non-cash goodwill impairment; adjusted diluted EPS $0.50.
Centene reaffirms FY2025 adjusted diluted EPS forecast of ~$1.75 at Deutsche Bank summit
Management to present at Deutsche Bank 2025 Healthcare Summit on September 11, 2025 at 8:00 a.m. EDT.
Centene director Thomas Greco resigns effective Aug 22, 2025; board reduced to 9
Director Thomas R. Greco notified resignation effective August 22, 2025.
Centene director Wayne S. DeVeydt resigns effective August 1, 2025
Director Wayne S. DeVeydt resigned effective August 1, 2025.
Centene Q2 2025: diluted loss per share $(0.51); HBR rises to 93.0%
GAAP diluted loss per share $(0.51); adjusted diluted loss per share $(0.16).
Centene withdraws 2025 guidance due to $1.8B risk adjustment hit
Withdraws 2025 GAAP and adjusted EPS guidance; preliminary $1.8B net risk adjustment revenue reduction (~$2.75 EPS impact).
Centene shareholders re-elect 11 directors, approve 2025 stock plan, reject climate proposals
All 11 director nominees elected with 84-93% support; Sarah M. London received highest for-votes at 99.6%.
Centene reaffirms FY 2025 GAAP EPS >$6.19, adjusted EPS >$7.25
Reaffirmed FY 2025 GAAP diluted EPS floor of above $6.19 and adjusted diluted EPS floor of above $7.25.
Centene Q1 adjusted EPS $2.90 beats $2.26 YoY; raises FY revenue guidance by $6B
Adjusted diluted EPS of $2.90 vs $2.26 in Q1 2024 (+28%); GAAP EPS $2.63.
Centene reaffirms FY2025 adjusted EPS guidance above $7.25 at Barclays conference
Reaffirms 2025 adjusted diluted EPS guidance of greater than $7.25.
Centene enters $6B credit facility, replacing prior agreement
New $6B facility includes a $4B revolving credit and a $2B term loan, maturing March 5, 2030.
Centene reaffirms FY2025 adjusted EPS guidance floor of >$7.25
Management to reaffirm 2025 adjusted diluted EPS guidance of >$7.25 during March 4 investor meetings.
Centene appoints former Prudential CFO Kenneth Tanji to Board of Directors
Mr. Tanji elected to Board effective Feb 20, 2025, expanding Board from 11 to 12 members.
Centene Q4/FY2024: adj EPS $7.17 (+7% YoY), raises 2025 revenue guide by $4B
Full year 2024 adjusted diluted EPS $7.17, up 7% from $6.68; GAAP EPS $6.31.
Centene announces 2025 adj. EPS guidance >$7.25, 6% YoY growth; reaffirms 2024
2025 adj. diluted EPS guidance >$7.25; GAAP diluted EPS >$6.19.
Centene reaffirms FY2024 adjusted EPS >$6.80, foresees 2025 growth
Centene reaffirms FY2024 adjusted diluted EPS guidance of greater than $6.80.
Centene President Ken Fasola to retire July 1, 2025; will serve as Strategic Advisor until then
Kenneth J. Fasola notified Centene of his retirement on Nov 8, 2024; effective July 1, 2025.
Centene Q3 adjusted EPS $1.62, revenue $36.9B, reaffirms FY24 adjusted EPS guidance >$6.80
Adjusted diluted EPS of $1.62; GAAP EPS $1.36. Premium + service revenue $36.9B (+6% YoY).
Centene MA Star Ratings improve: 46% of members in 3.5+ star plans vs 23% prior year
CMS released 2025 Medicare Advantage Star Ratings on Oct 10, 2024; Centene's membership in plans rated 3.5+ stars rose to ~46% from ~23% year-over-year.
Centene assigns Director Thomas R. Greco to Governance and Compensation Committees
Amendment to Aug 15 8-K adds committee assignments for newly appointed director.
Director Lori J. Robinson to leave Centene board at 2025 annual meeting
Robinson notified Centene on Sept 25, 2024 she will not stand for re-election.
Centene reaffirms FY2024 adjusted EPS guidance >$6.80 at investor meetings
Reaffirms full-year 2024 adjusted diluted EPS guidance >$6.80 at BofA conference and investor meetings.
Centene reaffirms FY 2024 adjusted EPS guidance >$6.80, shifts 20-30 cents from Q3 to Q4
Reaffirms FY2024 adjusted diluted EPS guidance greater than $6.80; Q3 adjusted EPS projected at $1.31-$1.41.
Centene elects Thomas Greco to board of directors, expanding to 11 members
Thomas Greco appointed to Centene board effective Aug. 9, 2024; term runs through 2025 annual meeting.
Centene Q2 2024 adjusted EPS $2.42 (+15% YoY); reaffirms FY adj. EPS floor >$6.80
Adjusted diluted EPS $2.42, up 15% from $2.10 in Q2 2023; GAAP diluted EPS $2.16.
Centene books $0.7B net risk adjustment gain; prelim Q2 adj. EPS $2.42
CMS final 2023 risk adjustment receivable $0.0B vs. Centene's $1.3B net payable recorded.
Centene reaffirms FY adj EPS >$6.80, adds $125M reserve for 2025 MA bids; Medicaid costs elevated
Reaffirmed FY2024 adjusted diluted EPS >$6.80 and consolidated health benefits ratio 87.3%-87.9%.
All 10 director nominees elected with 460-476M votes for; broker non-votes of 16.99M on each.
Centene Q1 adjusted EPS $2.26 beats; raises FY2024 guidance to >$6.80
GAAP diluted EPS $2.16; adjusted diluted EPS $2.26 (+7% YoY); premium & service revenues $36.3B (+4% YoY).
On November 8, 2024, Kenneth J. Fasola, President of Centene Corporation (the "Company"), informed the Company that he intends to retire from the Company on July 1, 2025.
On September 25, 2024, Director Lori J. Robinson notified Centene Corporation (the “Company”) of her decision not to stand for re-election when her term expires at the Company’s 2025 Annual Meeting.
elected Thomas Greco to the Board to fill the resulting vacancy
Max materiality 0.85 · Median 0.50 · Most common event earnings